Advanced Melanoma Clinical Trials in Los Angeles, California

4 studies are recruiting for advanced melanoma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regi…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    The Angeles Clinic and Research Institute, Los Angeles, California
    Locations
    81 in total
    Run by
    Replimune, Inc.

    See if you can join NCT06264180 on ClinicalTrials.gov

  2. A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

    The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Locations
    12 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06594991 on ClinicalTrials.gov

  3. Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

    The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Helios Clinical Research, Los Angeles, California
    Locations
    107 in total
    Run by
    Eikon Therapeutics

    See if you can join NCT06697301 on ClinicalTrials.gov

  4. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Angeles Clinic and Research Institute- West Los Angeles, Los Angeles, California
    Locations
    211 in total
    Run by
    Immunocore Ltd

    See if you can join NCT06112314 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.